|Year : 2020 | Volume
| Issue : 3 | Page : 230-234
Effect of tamoxifen-loaded transdermal patch on physical and biochemical parameters in DMBA-induced breast cancer
Anjana Adhyapak1, BG Desai2
1 Department of Pharmaceutical Quality Assurance, KLE College of Pharmacy, KLE Academy of Higher Education and Research, Belagavi, Karnataka, India
2 Department of Pharmaceutics, KLE College of Pharmacy, KLE Academy of Higher Education and Research, Belagavi, Karnataka, India
|Date of Submission||08-Feb-2020|
|Date of Acceptance||13-Jul-2020|
|Date of Web Publication||05-Oct-2020|
Ms. Anjana Adhyapak
Department of Pharmaceutical Quality Assurance, KLE College of Pharmacy, Belagavi, KLE Academy of Higher Education and Research, Belagavi - 590 010, Karnataka
Source of Support: None, Conflict of Interest: None
Background: The current study assessed the effect of tamoxifen-loaded transdermal patch in Dimethylbenz(a)anthracene (DMBA)-induced breast cancer.
Materials and Methods: Different formulations composed of various concentrations of tamoxifen citrate, poly (SA: RA), glucose, mannitol were formulated and were evaluated in DMBAinduced breast cancer in female albino Wistar rats. Multiple parameters such as body weight, hemoglobin content, red blood cell, white blood cell, SGPT, and SGOT were evaluated.
Results: Treatment with formulations showed a decrease in body weight contrast to disease. Equally, a considerable increase in hemoglobin was observed in the formulation treated group over disease grouping. Likewise, there decrease in SGPT and SGOT in formulation compared to disease.
Conclusion: The present study revealed a transdermal patch loaded with tamoxifen showed promising antitumor activity.
Keywords: Anticancer, nanoformulation, tamoxifen, transdermal patch
|How to cite this article:|
Adhyapak A, Desai B G. Effect of tamoxifen-loaded transdermal patch on physical and biochemical parameters in DMBA-induced breast cancer. Indian J Health Sci Biomed Res 2020;13:230-4
|How to cite this URL:|
Adhyapak A, Desai B G. Effect of tamoxifen-loaded transdermal patch on physical and biochemical parameters in DMBA-induced breast cancer. Indian J Health Sci Biomed Res [serial online] 2020 [cited 2021 Jan 22];13:230-4. Available from: https://www.ijournalhs.org/text.asp?2020/13/3/230/297196
| Introduction|| |
Patients with carcinoma are prescribed with tamoxifen for prophylactic care in pre- and postmenopausal females. It is a triphenylethylene derivative (nonsteroidal) and competes with steroids for steroid receptor positive in carcinoma cells. However, this agent is associated with multiple side effects such as multifocal viscous, fatty infiltration, hepatotoxicity, viscous sphacelus, and blood disorders.,
Formulation loaded with tamoxifen in the transdermal patch would possess lower hepatotoxicity and hemolytic carcinoma possessing higher patient adherence to treatment. This system plays an important role in promoting pharmacokinetic profile, enhancing efficacy, followed by minimization of toxicity  which could be the outcome of minimal particle size possessing them to penetrate biological barriers., Nanoparticles can be helpful as controlled release system, applied for cancer medical care and decrease the exploding of multiple side effects. Hence, the present study aimed to investigate the tamoxifen-loaded transdermal patch against breast carcinoma. Formulations were composed of a drug (tamoxifen), polymer (poly (SA:RA), and cryoprotectant (glucose and mannitol) at multiple concentrations. The detail of multiple formulations is summarized in [Table 1].
| Materials and Methods|| |
Evaluation of in vivo antitumor property
The study was performed after performing acute toxicity as OECD 423 A mixture containing 25 mg of DMBA was dissolved in 1 ml of a vehicle and injected by subcutaneous route. Tumor yield was evaluated after the end of the study. Seven different which composed 12 female albino rats in each group were used. Each group comprised of 12 female albino rats.
- Group 1: The normal control
- Group 2: The cancer group negative control
- Group 3: The tamoxifen group positive control (PC)
- Group 4: F-1
- Group 5: F-2
- Group 6: F-3
- Group 7: F-4.
Test sample treatment
Tamoxifen was injected i. p. for PC. Normal group was injected with vehicle. Similarly, Groups 4, 5, 6, and 7 were treated with multiple formulations, and the study was carried for 30 days. At the end of the study, multiple physical and biochemical parameters were evaluated.
Body weight was measured at the end of the study, and each group was compared to evaluate the role of formulation in tumor treatment. Similarly, hematological parameters such as hemoglobin, white blood cell (WBC), and red blood cell (RBC) counts were also determined in peripheral blood. Further, serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamic-pyruvic transaminase (SGPT) were also quantified using commercially available kits. Institutional ethics approval was obtained from the institutional ethics committee Ref. No KLECOP/CPCSEA-Reg No 221/Res-13-2010.
| Results|| |
Effect on final body weight
In the disease group, there was a considerable increase in body weight compared to a normal group. Similarly, in the PC group, there was a considerable decrease in body weight compared to the cancer group. Similarly, formulation F1 showed a considerable decrease in body weight compared to the cancer group. Likewise, formulation F2 showed a considerable decrease in body weight compared to the cancer group. Further, the F3 group showed a considerable decrease compared to the cancer group. Similarly, the F4 group showed a considerable decrease compared to the cancer group [Figure 1].
|Figure 1: Effect of multiple formulations in body weight ***P < 0.001 compared to normal control, #P < 0.05, ##P < 0.01, ###P < 0.001 compared to cancer group|
Click here to view
Effect on hemoglobin content
The hemoglobin content in the disease group was found to be considerably decreased in the disease group compared to normal control. Similarly, there was a considerable increase in hemoglobin content in the PC compared to the disease group. Similarly, formulations F1, F3, and F4 also showed a considerable increase in hemoglobin content compared to the normal disease group. However, formulation F2 did not affect hemoglobin content compared to the disease group [Figure 2].
|Figure 2: Effect of formulations on hemoglobin content (gm/dl) ***P < 0.001 compared to normal group, ##P < 0.01 compared to disease control group|
Click here to view
Effect on red blood cell count
RBC count was considerably decreased in the disease group compared to a normal group and was increased in the PC compared to the disease group. There was an increase in RBC count in formulation treatments. However, the results were not considerable [Figure 3].
|Figure 3: Effect of formulations in red blood cell ***P < 0.001 compared to normal, ###P < 0.001 compared to disease group|
Click here to view
Effect on white blood cell count
There was a considerable decrease in WBC count in the disease group compared to the normal group. Similarly, there was a considerable increase in WBC count in PC compared to the disease group. There was an increase in WBC count in formulation treated groups; however, the results were not considerably different compared to the disease control group [Figure 4].
|Figure 4: Effect of formulations in white blood cell ***P < 0.001 compared to normal, ###P < 0.001 compared to disease group|
Click here to view
Effect on tumor weight
The PC group showed a considerable decrease in tumor weight in the PC group compared to the disease group. Likewise, treating with formulations F1 and F2 showed an equal level of a considerable decrease in tumor weight compared to disease control. Likewise, formulation F3 showed a considerable decrease in tumor weight compared to the disease group. However, formulation F4 had no effect in decreasing tumor weight compared to the disease group [Figure 5].
|Figure 5: Effect of formulations in tumor weight *P < 0.05, **P < 0.01, ***P < 0.001 compared to disease group|
Click here to view
Effect on SGPT
A considerable increase in the SGPT level was found in the disease group compared to normal. However, there was a considerable decrease in the SGPT level in tamoxifen and formulation (F1–F4)-treated groups. Furthermore, there was a decreased level in the SGPT level in formulations compared to the tamoxifen group [Figure 6].
|Figure 6: Effect on SGPT levels ***P < 0.001 compared to normal group, ###P < 0.001 compared to disease group|
Click here to view
Effect on SGOT level
SGOT level in the disease group was found to be considerably higher compared to normal. However, there was a considerable decrease in the SGOT level in tamoxifen and formulation (F1–F4)-treated groups. Furthermore, there was a decreased level in the SGOT level in formulations compared to the tamoxifen group [Figure 7].
|Figure 7: Effect on SGOT levels ***P < 0.001 compared to normal group, ###P < 0.001 compared to disease group|
Click here to view
| Discussion|| |
In the present study, we investigated four different formulations and were assessed for multiple parameters including body weight, tumor weight, RBC, WBC, and hemoglobin content. All the results were also compared with the gold standard treatment procedure for tamoxifen.
Nanoformulations are well-accepted formulations in the pharmacotherapy of multiple diseases including breast cancer. Further, breast cancer includes a polygenic risk for the development of its pathogenesis. It is more convenient in the pharmacotherapy of such polygenic conditions since the treating is quite easy and the drug release is fast through this approach. The present study also showed a decrease in tumor weight by formulations F1, F2, and F3. Likewise, there was a decrease in body weight in the formulation-treated group. This represents that the formations have the capacity to release the tamoxifen in the targeted site.
Furthermore, cancer is a polygenic condition. The pharmacotherapy of this condition could be complicated, though we target a specific molecule or protein. On the other hand, a single compound can modulate multiple proteins and regulate multiple pathways. Although the tamoxifen-loaded formulation has been studied in the present study, there is always a probability that it could modulate multiple proteins and pathways as previously predicted,,,, which needs to be still applied for tamoxifen-loaded formulations.
Previous literature suggests that there is a decrease in hemoglobin in cancer pathogenesis, which has been revealed by the formulation treated in the present study. Further, there was an increase in RBC and WBC, but the results were not considerable compared to the disease group. This reflects that the sympathomimetic relief has not been achieved within the lowered time which could be achieved after long-term treatment and is the scope of future study.
One of the major limitations in the pharmacotherapy of cancer is increased SGOT and SGPT levels reflecting the hepatotoxicity, which needs to be minimized. In our study, there was a decrease in the SGOT and SGPT levels after tamoxifen treatment. Further, our formulation showed a decreased level of SGOT and SGPT compared to the tamoxifen group, which could be the outcome of targeted drug delivery.
| Conclusion|| |
The present study demonstrated the anticancer activity of multiple formulations and their effectiveness in multiple biochemical and hematological parameters reflecting the importance of nanoparticles in cancer pharmacotherapy and targeted drug delivery system.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Heery M, Corbett P, Zelkowitz R. Precautions for patients taking tamoxifen. J Adv Pract Oncol 2018;9:78-83.
Maximov PY, Lee TM, Jordan VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol 2013;8:135-55.
Yang G, Nowsheen S, Aziz K, Georgakilas AG. Toxicity and adverse effects of tamoxifen and other anti-estrogen drugs. Pharmacol Ther 2013;139:392-404.
Gunasekaran T, Haile T, Nigusse T, Dhanaraju MD. Nanotechnology: An effective tool for enhancing bioavailability and bioactivity of phytomedicine. Asian Pac J Trop Biomed 2014;4:S1-7.
Zhang XQ, Xu X, Bertrand N, Pridgen E, Swami A, Farokhzad OC. Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. Adv Drug Deliv Rev 2012;64:1363-84.
De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine 2008;3:133-49.
Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S, O'Regan RM. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol 2006;7:657-67.
Mina LA, Arun B. Polygenic risk scores in breast cancer. Curr Breast Cancer Rep 2019;11:117.
Bredberg A. Cancer: More of polygenic disease and less of multiple mutations? A quantitative viewpoint. Cancer 2011;117:440-5.
Khanal P, Patil BM, Mandar BK, Dey YN, Duyu T. Network pharmacology-based assessment to elucidate the molecular mechanism of anti-diabetic action of Tinospora cordifolia
. Clin Phytosci 2019;5:35.
Khanal P, Patil BM. Gene set enrichment analysis of alpha-glucosidase inhibitors from Ficus benghalensis
. Asian Pac J Trop Biomed 2019;9263-70.
Khanal P, Mandar BK, Patil BM, Hullatti KK. In silico
antidiabetic screening of Borapetoside C, Cordifolioside A and Magnoflorine. Indian J Pharm Sci 2019;81:550-5.
Khanal P, Mandar BK, Magadum P, Patil BM, Hullatti KK. In silico
docking study of limonoids from Azadirachta indica
with pfpk5: A novel target for Plasmodium falciparum
. Indian J Pharm Sci 2019;81:326-32.
Patil VS, Biradar PR, Attar V, Khanal P. In silico
docking analysis of active biomolecules from Cissus quadrangularis
L. against PPAR-γ. Indian J Pharm Educ 2019;53:S332-7.
Dicato M, Plawny L, Diederich M. Anemia in cancer. Ann Oncol 2010;21 Suppl 7:vii167-72.
Singh TD, Barbhuiya MA, Poojary S, Shrivastav BR, Tiwari PK. The liver function test enzymes and glucose level are positively correlated in gallbladder cancer: A cancer registry data analysis from North central India. Indian J Cancer 2012;49:125-36.
] [Full text]
[Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7]